> News
 > Everimmune launches Phase I clinical trial for its oncobiotic drug candidate in lung and kidney cancer
News
16/01/2023

Everimmune launches Phase I clinical trial for its oncobiotic drug candidate in lung and kidney cancer

Villejuif-Grand Paris, France, January 16, 2023 – EverImmune, a clinical-stage biotechnology company specialized in the development of live biotherapeutic products in the field of microbiota oncology, today announces that a first patient has been treated in its phase I clinical trial (EV 2101) evaluating Oncobax® AK in lung and kidney cancer patients. The aim of the trial is to assess the […]

Access the press release

 

Our news

News
23/01/2024
Focus SoHO et Paquet Pharma
> READ
09/11/2023
Alliance Promotion Microbiote To Welcome Ferring Pharmaceuticals, Pelican Health and Polepharma as New Members
> READ
News
29/11/2022
TargEDys and SymbioPharm enter an exclusive partnership to launch SymbioLife® Satylia® in Germany
> READ
> See all news